IRLAB Therapeutics AB (publ) (IRLAB-A) — Cash Flow-to-Debt Ratio
IRLAB Therapeutics AB (publ) (IRLAB-A) has a Cash Flow-to-Debt Ratio of -0.22x as of December 2025, meaning its operating cash flow of Skr-24.18 Million could theoretically repay 0% of its total liabilities (Skr107.49 Million) in one year. See IRLAB Therapeutics AB (publ) (IRLAB-A) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
IRLAB Therapeutics AB (publ) Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for IRLAB Therapeutics AB (publ) across 12 annual periods. Also explore IRLAB Therapeutics AB (publ) (IRLAB-A) equity growth momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for IRLAB Therapeutics AB (publ) (2014–2025)
Year-by-year debt coverage analysis for IRLAB Therapeutics AB (publ). For market capitalisation and broader financial context, see IRLAB-A stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.51x | Skr-55.22 Million | Skr107.49 Million | ▲ +18.9% |
| 2024 | -0.63x | Skr-65.59 Million | Skr103.58 Million | ▲ +76.4% |
| 2023 | -2.69x | Skr-164.85 Million | Skr61.36 Million | ▲ +38.3% |
| 2022 | -4.36x | Skr-142.61 Million | Skr32.72 Million | ▼ -347.2% |
| 2021 | 1.76x | Skr128.64 Million | Skr72.97 Million | ▲ +143.8% |
| 2020 | -4.02x | Skr-89.21 Million | Skr22.19 Million | ▼ -15.7% |
| 2019 | -3.48x | Skr-91.20 Million | Skr26.24 Million | ▲ +38.8% |
| 2018 | -5.68x | Skr-70.79 Million | Skr12.46 Million | ▲ +21.6% |
| 2017 | -7.24x | Skr-57.74 Million | Skr7.97 Million | ▼ -63.7% |
| 2016 | -4.43x | Skr-40.82 Million | Skr9.22 Million | ▼ -45.1% |
| 2015 | -3.05x | Skr-27.66 Million | Skr9.06 Million | ▼ -394.1% |
| 2014 | -0.62x | Skr-11.02 Million | Skr17.86 Million | — |